PL4000615T3 - Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek - Google Patents
Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerekInfo
- Publication number
- PL4000615T3 PL4000615T3 PL20207534.7T PL20207534T PL4000615T3 PL 4000615 T3 PL4000615 T3 PL 4000615T3 PL 20207534 T PL20207534 T PL 20207534T PL 4000615 T3 PL4000615 T3 PL 4000615T3
- Authority
- PL
- Poland
- Prior art keywords
- dual
- renal diseases
- tnfr2 agonists
- tnfr1 antagonists
- tnfr1
- Prior art date
Links
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 title 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207534.7A EP4000615B1 (en) | 2020-11-13 | 2020-11-13 | Dual tnfr1 antagonists and tnfr2 agonists for use in renal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4000615T3 true PL4000615T3 (pl) | 2022-12-19 |
Family
ID=73448924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20207534.7T PL4000615T3 (pl) | 2020-11-13 | 2020-11-13 | Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230414562A1 (pl) |
| EP (1) | EP4000615B1 (pl) |
| JP (1) | JP7462116B2 (pl) |
| CN (1) | CN116568296A (pl) |
| AU (1) | AU2021378077B2 (pl) |
| CA (1) | CA3197986A1 (pl) |
| ES (1) | ES2930093T3 (pl) |
| PL (1) | PL4000615T3 (pl) |
| WO (1) | WO2022101389A1 (pl) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2533652T3 (es) | 2006-01-18 | 2015-04-13 | Evolva Sa | Moduladores de PPAR |
| AU2008206049A1 (en) * | 2007-01-18 | 2008-07-24 | Evolva Sa | Substituted 1,3-dioxanes and their uses |
| MX2009007669A (es) | 2007-01-18 | 2011-12-08 | Evolva Sa | 1,3,-dioxanos sustituidos y sus usos. |
| US20160193179A1 (en) | 2012-12-18 | 2016-07-07 | Kjell Steinar Sakariassen | Treatment of Cardiovascular Risk in Diabetic Patients |
-
2020
- 2020-11-13 ES ES20207534T patent/ES2930093T3/es active Active
- 2020-11-13 EP EP20207534.7A patent/EP4000615B1/en active Active
- 2020-11-13 PL PL20207534.7T patent/PL4000615T3/pl unknown
-
2021
- 2021-11-12 CA CA3197986A patent/CA3197986A1/en active Pending
- 2021-11-12 AU AU2021378077A patent/AU2021378077B2/en active Active
- 2021-11-12 US US18/252,339 patent/US20230414562A1/en active Pending
- 2021-11-12 JP JP2023528450A patent/JP7462116B2/ja active Active
- 2021-11-12 WO PCT/EP2021/081482 patent/WO2022101389A1/en active Application Filing
- 2021-11-12 CN CN202180074898.5A patent/CN116568296A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3197986A1 (en) | 2022-05-19 |
| AU2021378077A1 (en) | 2023-05-25 |
| CN116568296A (zh) | 2023-08-08 |
| US20230414562A1 (en) | 2023-12-28 |
| JP2023554588A (ja) | 2023-12-28 |
| AU2021378077B2 (en) | 2024-03-14 |
| WO2022101389A1 (en) | 2022-05-19 |
| JP7462116B2 (ja) | 2024-04-04 |
| EP4000615B1 (en) | 2022-10-19 |
| EP4000615A1 (en) | 2022-05-25 |
| ES2930093T3 (es) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL200572A0 (en) | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
| IL276872A (en) | Dosage for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies | |
| CL2013002869A1 (es) | Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona. | |
| SG10202006466YA (en) | Managing transactions in multiple blockchain networks | |
| WO2010136492A3 (en) | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye. | |
| ZA202206885B (en) | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof | |
| IL278079A (en) | Inhalable liposomal sustained release compound for use in the treatment of pulmonary disease | |
| IL274836A (en) | Dosing plan of vidofludimus for use in the prevention or treatment of chronic inflammatory diseases and/or autoimmune diseases | |
| SG10202006451QA (en) | Managing transactions in multiple blockchain networks | |
| IL290256A (en) | Anti-pd-1 antibody and its medical use | |
| CL2011002416A1 (es) | Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit. | |
| SG10202006447VA (en) | Managing transactions in multiple blockchain networks | |
| IL277634A (en) | Leptin receptor agonist antibody for use in the treatment of metabolic dysfunction or hypoleptinemia | |
| IL289354A (en) | Anti-154cd antibodies and their uses | |
| IL278207A (en) | Use of neutrophil elastase inhibitors in liver disease | |
| EP4034132A4 (en) | ERK5 DEGRADER AS THERAPEUTIC FOR CANCER AND INFLAMMATORY DISEASES | |
| EP3898625C0 (en) | NEW COMPOUNDS AND THEIR THERAPEUTIC USE | |
| DOP2016000003A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
| PL4000615T3 (pl) | Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek | |
| EP3617224A4 (en) | SN 10 SELECTIVE ANTAGONIST OF TNFR1 AND ITS USE TO TREAT INFLAMMATORY DISEASE OF THE INTESTINE | |
| IL291661A (en) | Dosage for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL242748B (en) | Nmdar agonists for use in the treatment of autoimmune-induced glutamatergic receptor dysfunction | |
| MX2013013182A (es) | Tratamiento de la mastitis. | |
| TWI799398B (zh) | 供用於多層結構中之聚合物摻合物及包含所述聚合物摻合物之多層結構 |